Efficacy and safety of novel NK-1 antagonist, Fosaprepitant for the prevention of CINV
Not Applicable
- Conditions
- Patients receiving highly or moderately emetogenic agents
- Registration Number
- JPRN-UMIN000007376
- Lead Sponsor
- Kobe City Medical Center General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients having past history of hypersensitivity to fosaprepitant 2)Used Pimozide
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method